{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:38:36Z","timestamp":1760060316204,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background and Clinical Significance: Zoledronic acid (ZA) is a widely used bisphosphonate for the prevention of skeletal-related events in patients with metastatic bone disease. While it is generally well tolerated, rare immune-mediated complications may be underrecognized. To date, myocarditis has not been reported in association with ZA. Case Presentation: A 35-year-old woman with metastatic pheochromocytoma developed acute, non-exertional chest pain approximately 36 h after receiving her first intravenous ZA infusion. Laboratory testing revealed elevated high-sensitivity troponin T, peaking at 1182 ng\/L. Cardiac magnetic resonance imaging (CMR) demonstrated myocardial edema and subepicardial late gadolinium enhancement, consistent with acute myocarditis per the 2018 revised Lake Louise criteria. An extensive diagnostic workup excluded infectious, autoimmune, and ischemic causes. Symptoms and troponin levels improved following ZA discontinuation and supportive care. In the absence of alternative etiologies, and given the close temporal association with ZA administration, the diagnosis of presumed ZA-associated myocarditis was supported by clinical presentation, biochemical markers, and CMR findings, recognizing that histopathological confirmation is rarely pursued in clinically stable patients. Conclusions: To our knowledge, this is the first reported case of presumed zoledronic acid\u2013associated myocarditis confirmed by cardiac MRI. This report highlights the diagnostic utility of CMR in suspected drug-related cardiac inflammation and the importance of considering myocarditis in patients presenting with unexplained chest pain following ZA infusion, particularly when other causes have been excluded.<\/jats:p>","DOI":"10.3390\/diagnostics15162064","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:31:37Z","timestamp":1755516697000},"page":"2064","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute Myocarditis Following Zoledronic Acid Infusion: Cardiac MRI Diagnosis of a Rare Cardiotoxic Event with Contextual Literature Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-1825","authenticated-orcid":false,"given":"Ismaell","family":"Massalha","sequence":"first","affiliation":[{"name":"The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"},{"name":"Department of Oncology, Ziv Medical Center, Safed 13100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Zabit","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aryeh","family":"Shalev","sequence":"additional","affiliation":[{"name":"Department of Radiology, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-2086","authenticated-orcid":false,"given":"Gal","family":"Ben-Arie","sequence":"additional","affiliation":[{"name":"Department of Radiology, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jbmr.3880","article-title":"What Else Do We Need? A Commentary on Zoledronate Effects on Cancer and Cardiac Events","volume":"35","author":"Leder","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100470","DOI":"10.1016\/j.jbo.2023.100470","article-title":"Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis","volume":"39","author":"Lorange","year":"2023","journal-title":"J. Bone Oncol."},{"key":"ref_3","first-page":"1029","article-title":"Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: Systematic review and me-ta-analysis of randomized controlled trials","volume":"26","author":"Menshawy","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_4","first-page":"e12541","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11864-019-0623-8","article-title":"Role of Bisphosphonates in Breast Cancer Therapy","volume":"20","author":"Goldvaser","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_6","first-page":"399","article-title":"Bisphosphonates for cancer patients: Why, how, and when? Supportive Care in Cancer [Internet]","volume":"10","author":"Body","year":"2002","journal-title":"Support. Care Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/11584720-000000000-00000","article-title":"Impact of bisphosphonates on the risk of atrial fibrillation","volume":"10","author":"Howard","year":"2010","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e39188","DOI":"10.1097\/MD.0000000000039188","article-title":"Severe sepsis induced by zoledronic acid A case report","volume":"103","author":"Liao","year":"2024","journal-title":"Medicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5694\/mja13.11524","article-title":"Acute myopericarditis following intravenous zoledronic acid for the treatment of Paget\u2019s disease","volume":"200","author":"Watts","year":"2014","journal-title":"Med. J. Aust."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated with Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1148\/radiol.211765","article-title":"Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor\u2013induced Myocarditis","volume":"303","author":"Cadour","year":"2022","journal-title":"Radiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clinthera.2010.03.014","article-title":"Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis","volume":"32","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/imm.13283","article-title":"Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of \u03b3\u03b4 T cells","volume":"162","author":"Takimoto","year":"2021","journal-title":"Immunology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.091201","article-title":"Atrial fibrillation and bisphosphonate therapy","volume":"25","author":"Pazianas","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11657-025-01523-6","article-title":"Orbital inflammation following zoledronic acid infusion","volume":"20","author":"Liu","year":"2025","journal-title":"Arch. Osteoporos."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"116647","DOI":"10.1016\/j.bone.2022.116647","article-title":"Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study","volume":"168","author":"Nerlekar","year":"2023","journal-title":"Bone"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152304","DOI":"10.1016\/j.semarthrit.2023.152304","article-title":"Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review","volume":"64","author":"Liu","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_18","first-page":"e41524","article-title":"A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response","volume":"15","author":"Jamil","year":"2023","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.joen.2023.08.010","article-title":"Zoledronic Acid Modulates Cytokine Expression and Mitigates Bone Loss during the Development of Induced Apical Periodontitis in a Mice Model","volume":"49","author":"Maia","year":"2023","journal-title":"J. Endod."},{"key":"ref_20","unstructured":"Greear, E.L., Patel, P., and Bankole, A. (2025, April 15). Zoledronate, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585053\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women","volume":"35","author":"Reid","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2021.11.017","article-title":"Multiparametric Cardiovascular Magnetic Resonance Approach in Diagnosing","volume":"15","author":"Eichhorn","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"85","author":"Drazner","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e10793","DOI":"10.1002\/jbm4.10793","article-title":"Cardiovascular Safety in Postmeno-pausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post-Authorization Safety Study","volume":"7","author":"Spangler","year":"2023","journal-title":"JBMR Plus"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/16\/2064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:29:54Z","timestamp":1760034594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/16\/2064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":25,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["diagnostics15162064"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15162064","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}